Project Confirm: Accelerated Drug Approvals for CML-Letter
Clin Cancer Res. 2024 Jan 5;30(1):235-236. doi: 10.1158/1078-0432.CCR-23-2630.NO ABSTRACTPMID:38178775 | DOI:10.1158/1078-0432.CCR-23-2630 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 5, 2024 Category: Cancer & Oncology Authors: Jan H Beumer Salvatore J Salamone Source Type: research
Project Confirm: Accelerated Drug Approvals for CML-Response
Clin Cancer Res. 2024 Jan 5;30(1):237-238. doi: 10.1158/1078-0432.CCR-23-3234.NO ABSTRACTPMID:38178776 | DOI:10.1158/1078-0432.CCR-23-3234 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 5, 2024 Category: Cancer & Oncology Authors: Kendra L Sweet Jorge E Cortes Jane F Apperley Mel Mann Michael J Mauro Vivian G Oehler Cristina Ruiz Charles A Schiffer Lori A Ehrlich Gulsum E Pamuk Joseph Wynne Gautam U Mehta Olanrewaju O Okusanya R Angelo de Claro Marc R Theoret B Douglas Smith Kelly Source Type: research
Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
CONCLUSIONS: SMARCA4-mutant SCLC-Y cell lines exhibit characteristics consistent with SMARCA4-deficient malignancies rather than SCLC. Our findings suggest that, unlike ASCL1, NEUROD1, and POU2F3, YAP1 is not a subtype defining transcription factor in SCLC.PMID:38180245 | DOI:10.1158/1078-0432.CCR-23-2360 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 5, 2024 Category: Cancer & Oncology Authors: Jin Ng Ling Cai Luc Girard Owen W J Prall Neeha Rajan Christine Khoo Ahida Batrouney David J Byrne Danielle K Boyd Ariena J Kersbergen Michael Christie John D Minna Marian L Burr Kate D Sutherland Source Type: research
An immune gene expression risk score for distant metastases after radiotherapy for cervical cancer
CONCLUSION: The immune metastatic risk score addresses important challenges in the treatment of cervical cancer - identifying patients at high risk of DM after radiotherapy. The findings of this study indicate that high tumor mutational burden and a 'cold', immune-excluded tumor microenvironment influence distant metastatic recurrence. Further validation of the risk score is needed.PMID:38180733 | DOI:10.1158/1078-0432.CCR-23-2085 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 5, 2024 Category: Cancer & Oncology Authors: Jelena Lukovic Melania Pintilie Kathy Han Anthony W Fyles Jeff P Bruce Rene Quevedo Trevor J Pugh Christina S Fjeldbo Heidi Lyng Michael F Milosevic Source Type: research
Project Confirm: Accelerated Drug Approvals for CML-Letter
Clin Cancer Res. 2024 Jan 5;30(1):235-236. doi: 10.1158/1078-0432.CCR-23-2630.NO ABSTRACTPMID:38178775 | DOI:10.1158/1078-0432.CCR-23-2630 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 5, 2024 Category: Cancer & Oncology Authors: Jan H Beumer Salvatore J Salamone Source Type: research
Project Confirm: Accelerated Drug Approvals for CML-Response
Clin Cancer Res. 2024 Jan 5;30(1):237-238. doi: 10.1158/1078-0432.CCR-23-3234.NO ABSTRACTPMID:38178776 | DOI:10.1158/1078-0432.CCR-23-3234 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 5, 2024 Category: Cancer & Oncology Authors: Kendra L Sweet Jorge E Cortes Jane F Apperley Mel Mann Michael J Mauro Vivian G Oehler Cristina Ruiz Charles A Schiffer Lori A Ehrlich Gulsum E Pamuk Joseph Wynne Gautam U Mehta Olanrewaju O Okusanya R Angelo de Claro Marc R Theoret B Douglas Smith Kelly Source Type: research
Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
CONCLUSIONS: SMARCA4-mutant SCLC-Y cell lines exhibit characteristics consistent with SMARCA4-deficient malignancies rather than SCLC. Our findings suggest that, unlike ASCL1, NEUROD1, and POU2F3, YAP1 is not a subtype defining transcription factor in SCLC.PMID:38180245 | DOI:10.1158/1078-0432.CCR-23-2360 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 5, 2024 Category: Cancer & Oncology Authors: Jin Ng Ling Cai Luc Girard Owen W J Prall Neeha Rajan Christine Khoo Ahida Batrouney David J Byrne Danielle K Boyd Ariena J Kersbergen Michael Christie John D Minna Marian L Burr Kate D Sutherland Source Type: research
An immune gene expression risk score for distant metastases after radiotherapy for cervical cancer
CONCLUSION: The immune metastatic risk score addresses important challenges in the treatment of cervical cancer - identifying patients at high risk of DM after radiotherapy. The findings of this study indicate that high tumor mutational burden and a 'cold', immune-excluded tumor microenvironment influence distant metastatic recurrence. Further validation of the risk score is needed.PMID:38180733 | DOI:10.1158/1078-0432.CCR-23-2085 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 5, 2024 Category: Cancer & Oncology Authors: Jelena Lukovic Melania Pintilie Kathy Han Anthony W Fyles Jeff P Bruce Rene Quevedo Trevor J Pugh Christina S Fjeldbo Heidi Lyng Michael F Milosevic Source Type: research
Project Confirm: Accelerated Drug Approvals for CML-Letter
Clin Cancer Res. 2024 Jan 5;30(1):235-236. doi: 10.1158/1078-0432.CCR-23-2630.NO ABSTRACTPMID:38178775 | DOI:10.1158/1078-0432.CCR-23-2630 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 5, 2024 Category: Cancer & Oncology Authors: Jan H Beumer Salvatore J Salamone Source Type: research
Project Confirm: Accelerated Drug Approvals for CML-Response
Clin Cancer Res. 2024 Jan 5;30(1):237-238. doi: 10.1158/1078-0432.CCR-23-3234.NO ABSTRACTPMID:38178776 | DOI:10.1158/1078-0432.CCR-23-3234 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 5, 2024 Category: Cancer & Oncology Authors: Kendra L Sweet Jorge E Cortes Jane F Apperley Mel Mann Michael J Mauro Vivian G Oehler Cristina Ruiz Charles A Schiffer Lori A Ehrlich Gulsum E Pamuk Joseph Wynne Gautam U Mehta Olanrewaju O Okusanya R Angelo de Claro Marc R Theoret B Douglas Smith Kelly Source Type: research
Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
CONCLUSIONS: SMARCA4-mutant SCLC-Y cell lines exhibit characteristics consistent with SMARCA4-deficient malignancies rather than SCLC. Our findings suggest that, unlike ASCL1, NEUROD1, and POU2F3, YAP1 is not a subtype defining transcription factor in SCLC.PMID:38180245 | DOI:10.1158/1078-0432.CCR-23-2360 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 5, 2024 Category: Cancer & Oncology Authors: Jin Ng Ling Cai Luc Girard Owen W J Prall Neeha Rajan Christine Khoo Ahida Batrouney David J Byrne Danielle K Boyd Ariena J Kersbergen Michael Christie John D Minna Marian L Burr Kate D Sutherland Source Type: research
An immune gene expression risk score for distant metastases after radiotherapy for cervical cancer
CONCLUSION: The immune metastatic risk score addresses important challenges in the treatment of cervical cancer - identifying patients at high risk of DM after radiotherapy. The findings of this study indicate that high tumor mutational burden and a 'cold', immune-excluded tumor microenvironment influence distant metastatic recurrence. Further validation of the risk score is needed.PMID:38180733 | DOI:10.1158/1078-0432.CCR-23-2085 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 5, 2024 Category: Cancer & Oncology Authors: Jelena Lukovic Melania Pintilie Kathy Han Anthony W Fyles Jeff P Bruce Rene Quevedo Trevor J Pugh Christina S Fjeldbo Heidi Lyng Michael F Milosevic Source Type: research
Levetiracetam: a potent sword against microglia polarization in gliomas
Clin Cancer Res. 2024 Jan 3. doi: 10.1158/1078-0432.CCR-23-3322. Online ahead of print.ABSTRACTCrosstalk between tumor cells and peritumoral cells contributes to immunosuppressive microenvironment formation in glioblastomas (GBMs). A recent study revealed that glioma stem cells activated neuronal activity to promote microglial M2 polarization for leading to GBM progression, which could be pharmacologically blocked by Levetiracetam, providing a practical strategy for GBM immunotherapy.PMID:38170191 | DOI:10.1158/1078-0432.CCR-23-3322 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 3, 2024 Category: Cancer & Oncology Authors: Xiaoteng Cui Qixue Wang Xiaomin Liu Chunsheng Kang Source Type: research
Tumor-associated Macrophages in Merkel Cell Carcinoma: Old Balances, New Checks
Clin Cancer Res. 2024 Jan 3. doi: 10.1158/1078-0432.CCR-23-3320. Online ahead of print.ABSTRACTA recent report sheds light on the tumor-associated macrophages (TAMs) in MCC, and the association of S100A8-expressing TAMs with resistance to anti-PD-(L)1 inhibitors. These data improve our understanding about why some tumors with brisk TIL do not respond to immunotherapy and provide a compelling rationale to target myeloid checkpoints in MCC.PMID:38170200 | DOI:10.1158/1078-0432.CCR-23-3320 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 3, 2024 Category: Cancer & Oncology Authors: Ann W Silk Diwakar Davar Source Type: research
Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA
CONCLUSIONS: Thus, ctDNA-based MRD monitoring appears to be a promising option to complement the overall assessment of pediatric AML patients, wherein patients with continuous ctDNA negativity have the option for treatment de-escalation in subsequent therapy. Importantly, patients with >3 log reduction but without clearance in ctDNA may not necessitate an aggressive treatment plan due to improved survival, but this needs further study to delineate.PMID:38170574 | DOI:10.1158/1078-0432.CCR-23-2589 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 3, 2024 Category: Cancer & Oncology Authors: Lipeng Liu Suyu Zong Aoli Zhang Yuanyuan Ren Benquan Qi Lixian Chang Wenyu Yang Xiaojuan Chen Yumei Chen Li Zhang Yao Zou Ye Guo Yingchi Zhang Min Ruan Xiaofan Zhu Source Type: research
